Benjamin Harkess, DPM
Podiatrist · Oklahoma City, OKNPI 1073871265
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $241, 2.9 times the $84 reported in 2019. That places this record below the midpoint for podiatrist clinicians in OK, where the typical reported total is $1,579.
Across 55 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$142
- Organogenesis Inc.$133
- Treace Medical Concepts, Inc.$132
- Smith+Nephew$117
- AbbVie$95
- Stryker$82
- plus $254 from 9 others
What the payments were for
- Food & beverage$955100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 7 | $142 |
| Organogenesis Inc. | 20 | $133 |
| Treace Medical Concepts, Inc. | 1 | $132 |
| Smith+Nephew | 7 | $117 |
| AbbVie | 4 | $95 |
| Stryker | 3 | $82 |
| Acera Surgical, Inc. | 3 | $53 |
| Johnson & Johnson | 2 | $48 |
| Next Science LLC | 2 | $46 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $26 |
| KCI USA, Inc. | 1 | $24 |
| Merck | 1 | $17 |
| Convatec Inc. | 1 | $14 |
| Gilead | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$955 in reported general payments places this provider in the 35th percentile of 54 podiatrist providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciclopirox | 60 | $1,500 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 67 | $891 |
| Gabapentin | 47 | $769 |
| Ciprofloxacin Hcl | 25 | $278 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $260 |
| Mupirocin | 30 | $199 |
| Cephalexin | 12 | $75 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Oklahoma City
- David CavallaroOklahoma City$22K
- Patricia BoehleOklahoma City$10K
- Andrea SeatOklahoma City$5K
- Angela SchuffOklahoma City$4K
- James FlynnOklahoma City$4K
- Terry NayfaOklahoma City$3K
- Kenneth GoldaOklahoma City$2K
- David WadeOklahoma City$2K
- Wolfgang KienzleOklahoma City$2K
- David leOklahoma City$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.